ProChon Biotech is planning to present results of a retrospective follow-up analysis of commercial patients that received the BioCart autologous cartilage system at the 9th World Congress of the International Cartilage Repair Society (ICRS) meeting in Barcelona.

In the study, 31 patients diagnosed with a single full-thickness cartilage defect, including those with previous knee operations, were followed for up to four years after treatment with the BioCart system.

ProChon said that the significant improvement over time from BioCart implantation was demonstrated via scoring on the International Knee Documentation Committee knee evaluation form and MRI mapping.

ProChon chief executive officer Patrick Donnell said that the ICRS World Congress is the premier venue for international collaboration in cartilaginous tissue research and they are pleased to introduce these compelling data sets to leading surgeons, scientists and clinical researchers.

“Our Phase II clinical study of the BioCart system in the US and Israel is entering the final stages of patient enrollment, which we anticipate completing early in the 2010 fourth quarter,” Donnell said.